JP2006516141A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006516141A5 JP2006516141A5 JP2004563692A JP2004563692A JP2006516141A5 JP 2006516141 A5 JP2006516141 A5 JP 2006516141A5 JP 2004563692 A JP2004563692 A JP 2004563692A JP 2004563692 A JP2004563692 A JP 2004563692A JP 2006516141 A5 JP2006516141 A5 JP 2006516141A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- derivative
- lipoxygenase inhibitor
- compound
- hydroxydodeca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 9
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 9
- WDEABJKSGGRCQA-UHFFFAOYSA-N docebenone Chemical class CC1=C(C)C(=O)C(CCCCC#CCCCC#CCO)=C(C)C1=O WDEABJKSGGRCQA-UHFFFAOYSA-N 0.000 claims 4
- JFJWVJAVVIQZRT-UHFFFAOYSA-N 2-phenyl-1,3-dihydropyrazole Chemical class C1C=CNN1C1=CC=CC=C1 JFJWVJAVVIQZRT-UHFFFAOYSA-N 0.000 claims 3
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical group CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- QAOAOVKBIIKRNL-UHFFFAOYSA-N 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid Chemical group OC(=O)C(C)(C)CC1=C(SC(C)(C)C)C2=CC(C(C)C)=CC=C2N1CC1=CC=C(Cl)C=C1 QAOAOVKBIIKRNL-UHFFFAOYSA-N 0.000 claims 2
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 230000037396 body weight Effects 0.000 claims 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims 2
- HCZKYJDFEPMADG-UHFFFAOYSA-N nordihydroguaiaretic acid Chemical group C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000003626 triacylglycerols Chemical class 0.000 claims 2
- CPXGGWXJNQSFEP-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]-3,4-dihydropyrazol-5-amine Chemical group C1CC(N)=NN1C1=CC=CC(C(F)(F)F)=C1 CPXGGWXJNQSFEP-UHFFFAOYSA-N 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940109262 curcumin Drugs 0.000 claims 1
- 235000012754 curcumin Nutrition 0.000 claims 1
- 239000004148 curcumin Substances 0.000 claims 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- CEUDWZXMLMKPNN-SOFGYWHQSA-N n-hydroxy-n-[(e)-3-(3-phenoxyphenyl)prop-2-enyl]acetamide Chemical group CC(=O)N(O)C\C=C\C1=CC=CC(OC=2C=CC=CC=2)=C1 CEUDWZXMLMKPNN-SOFGYWHQSA-N 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43441202P | 2002-12-19 | 2002-12-19 | |
| US51110303P | 2003-10-15 | 2003-10-15 | |
| US10/734,625 US20040198800A1 (en) | 2002-12-19 | 2003-12-15 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
| PCT/US2003/040254 WO2004058240A1 (en) | 2002-12-19 | 2003-12-18 | Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006516141A JP2006516141A (ja) | 2006-06-22 |
| JP2006516141A5 true JP2006516141A5 (enExample) | 2007-02-01 |
Family
ID=32686074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004563692A Pending JP2006516141A (ja) | 2002-12-19 | 2003-12-18 | 抗高脂血症剤および抗高血圧剤としてのリポキシゲナーゼ阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040198800A1 (enExample) |
| EP (1) | EP1572185A4 (enExample) |
| JP (1) | JP2006516141A (enExample) |
| AU (1) | AU2003303331A1 (enExample) |
| CA (1) | CA2510295A1 (enExample) |
| WO (1) | WO2004058240A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106014A1 (en) * | 2004-10-14 | 2006-05-18 | Sekhar Boddupalli | Methods for treating diabetes |
| US7405302B2 (en) * | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) * | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) * | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070244128A1 (en) * | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) * | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2007072503A2 (en) * | 2005-12-21 | 2007-06-28 | Panacea Biotec Ltd. | Combinations for managing inflammation and associated disorders |
| TW200920369A (en) * | 2007-10-26 | 2009-05-16 | Amira Pharmaceuticals Inc | 5-lipoxygenase activating protein (flap) inhibitor |
| US20110160249A1 (en) * | 2008-05-23 | 2011-06-30 | Schaab Kevin Murray | 5-lipoxygenase-activating protein inhibitor |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| SG175390A1 (en) | 2009-04-29 | 2011-12-29 | Amarin Corp Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US9770421B2 (en) * | 2013-03-15 | 2017-09-26 | Indanio Bioscience Inc. | Uses for idebenone and related benzoquinones in metabolic disorders and other PPAR α/γ related diseases and conditions |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4319039A (en) * | 1979-06-15 | 1982-03-09 | Merck & Co., Inc. | Preparation of ammonium salt of hypocholesteremic fermentation product |
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4294926A (en) * | 1979-06-15 | 1981-10-13 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| US4393075A (en) * | 1980-04-14 | 1983-07-12 | Takeda Chemical Industries, Ltd. | Quinone compounds and their use in suppressing the production of SRS-A in mammals |
| MX7065E (es) * | 1980-06-06 | 1987-04-10 | Sankyo Co | Un procedimiento microbiologico para preparar derivados de ml-236b |
| JPS5889191A (ja) * | 1981-11-20 | 1983-05-27 | Sankyo Co Ltd | ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法 |
| US5354772A (en) * | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
| US4486593A (en) * | 1983-01-19 | 1984-12-04 | The Upjohn Company | 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors |
| JPS60142981A (ja) * | 1983-12-28 | 1985-07-29 | Yoshitomi Pharmaceut Ind Ltd | ３−インド−ルカルボキサミド誘導体 |
| JPS6165869A (ja) * | 1984-09-07 | 1986-04-04 | Kyowa Hakko Kogyo Co Ltd | キノリン−ｎ−オキシド誘導体 |
| IE59397B1 (en) * | 1985-03-16 | 1994-02-23 | Wellcome Found | New aryl derivatives |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4820850A (en) * | 1987-07-10 | 1989-04-11 | Merck & Co., Inc. | Process for α-C-alkylation of the 8-acyl group on mevinolin and analogs thereof |
| JP3003148B2 (ja) * | 1989-01-05 | 2000-01-24 | 藤沢薬品工業株式会社 | チアゾール化合物、その製造法およびそれを含有する医薬組成物 |
| JP2783655B2 (ja) * | 1990-07-02 | 1998-08-06 | 帝人株式会社 | ヒドロキサム酸誘導体 |
| US5122534A (en) * | 1991-02-08 | 1992-06-16 | Pfizer Inc. | Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides |
| US5250547A (en) * | 1991-08-29 | 1993-10-05 | Syntex (U.S.A.) Inc. | Benzopyran derivatives |
| HU217629B (hu) * | 1991-12-12 | 2000-03-28 | Novartis Ag. | Eljárás fluvasztatint tartalmazó stabilizált gyógyszerkészítmények előállítására |
| US6191169B1 (en) * | 1992-08-28 | 2001-02-20 | City Of Hope | Human leukocyte 12-lipoxygenase and its role in the pathogenesis of disease states |
| US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| CZ293016B6 (cs) * | 1995-06-01 | 2004-01-14 | Sankyo Company Limited | Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem |
| DE10121252A1 (de) * | 2001-04-30 | 2002-11-07 | Christos C Zouboulis | Behandlung der Akne |
| CA2448741C (en) * | 2001-05-30 | 2010-06-22 | Kissei Pharmaceutical Co., Ltd. | Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor |
-
2003
- 2003-12-15 US US10/734,625 patent/US20040198800A1/en not_active Abandoned
- 2003-12-18 WO PCT/US2003/040254 patent/WO2004058240A1/en not_active Ceased
- 2003-12-18 JP JP2004563692A patent/JP2006516141A/ja active Pending
- 2003-12-18 EP EP03808460A patent/EP1572185A4/en not_active Withdrawn
- 2003-12-18 AU AU2003303331A patent/AU2003303331A1/en not_active Abandoned
- 2003-12-18 CA CA002510295A patent/CA2510295A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006516141A5 (enExample) | ||
| EP1915993B1 (en) | Synergistic combinations comprising a renin inhibitor for cardiovascular diseases | |
| US20240409514A1 (en) | Methods for inhibiting native and promiscuous uptake of monoamine neurotransmitters | |
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| EP2491923A3 (en) | Combinations of therapeutic agents for treating cancer | |
| JP2007016035A5 (enExample) | ||
| JP2009514878A5 (enExample) | ||
| JP2010526840A5 (enExample) | ||
| NZ569563A (en) | Methods for treating cutaneous lupus using aminoisoindoline compounds | |
| JP2004516266A (ja) | アムロジピンおよびベナゼブリルの治療的組み合わせ | |
| CN104023715B (zh) | 激酶抑制剂的副作用降低剂 | |
| WO2006116435A2 (en) | Methods of treating atherosclerosis | |
| JP2004532828A5 (enExample) | ||
| JP2003519228A5 (enExample) | ||
| JP2009517411A5 (enExample) | ||
| JP2005513014A5 (enExample) | ||
| TWI286935B (en) | Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and-or to obesity | |
| JP2002520315A5 (enExample) | ||
| JP2009515927A5 (enExample) | ||
| KR20060130619A (ko) | 유기 화합물의 조합물 | |
| CA2590224A1 (en) | Method for reduction, stabilization and prevention of rupture of lipid rich plaque | |
| JP2008522955A5 (enExample) | ||
| JP4677705B2 (ja) | 頭痛の予防および／または治療剤 | |
| FR2882263A1 (fr) | Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales | |
| JP2007509184A5 (enExample) |